1. Pink Sheet
  2. >>Geography

Global Coalition Develops Consistent Terminology To Support Decentralized Trials

 
• By Vibha Sharma

As regulatory agencies around the globe work on initiatives to support decentralized clinical trials, the Decentralized Trials & Research Alliance says a shared language is needed to facilitate the global adoption of such trials.

Senior Couple Telehealth Visit
Use Of Decentralized Methods Can Make Research Faster And More Efficient • Source: Alamy

A global multistakeholder group that is working to promote the adoption of decentralized clinical trials (DCTs) has developed a glossary of common terms to improve the international adoption of decentralized research.

The glossary is expected to solve two major challenges relating to the uptake of DCTs, said the Decentralized Trials & Research Alliance (DTRA), the non-profit organization that published the online...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from International

More from Geography

MAHA Commission Outlines Enhanced Research On Drug Safety In Children

 
• By Cathy Kelly

Research would include initiatives on reproducing industry-sponsored studies, postmarket surveillance, and studies of long-term neurodevelopmental and metabolic outcomes for commonly prescribed pediatric drugs.

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 
• By Derrick Gingery

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.